Research output per year
Research output per year
Fingerprint
Dive into the research topics where Torben Plesner is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Researchers
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
-
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
Facon, T., Moreau, P., Weisel, K., Goldschmidt, H., Usmani, S. Z., Chari, A., Plesner, T., Orlowski, R. Z., Bahlis, N., Basu, S., Hulin, C., Quach, H., O’Dwyer, M., Perrot, A., Jacquet, C., Venner, C. P., Raje, N., Tiab, M., Macro, M. & Frenzel, L. & 8 others, , Apr 2025, In: Leukemia. 39, 4, p. 942-950Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile13 Downloads (Pure) -
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
Moreau, P., Facon, T., Usmani, S. Z., Bahlis, N., Raje, N., Plesner, T., Orlowski, R. Z., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Tiab, M., Macro, M., Frenzel, L. & Leleu, X. & 6 others, , Mar 2025, In: Leukemia. 39, 3, p. 710-719Research output: Contribution to journal › Journal article › Research › peer-review
-
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study
Bahlis, N. J., Zonder, J., Karlin, L., Plesner, T., Paris, L., Wrobel, T., Hungria, V., Besemer, B., Crusoe, E., Silkjaer, T., Perrot, A., Moreau, P., Wu, K. L., Delimpasi, S., Dimopoulos, M. A., Levin, M. D., Mangiacavalli, S., Nnane, I., Kim, Y. J. & Krevvata, M. & 5 others, , 2025, In: Leukemia and Lymphoma. 66, 14, p. 2685-2696Research output: Contribution to journal › Journal article › Research › peer-review
-
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes
Perrot, A., Facon, T., Plesner, T., Usmani, S. Z., Kumar, S., Bahlis, N. J., Hulin, C., Orlowski, R. Z., Nahi, H., Mollee, P., Ramasamy, K., Roussel, M., Jaccard, A., Delforge, M., Karlin, L., Arnulf, B., Chari, A., Wang, G., Gupta-Werner, N. & Kaila, S. & 6 others, , May 2025, In: European Journal of Haematology. 114, 5, p. 883-889Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile -
LOW-DOSE VENETOCLAX-DEXAMETHASONE IN T(11;14)-POSITIVE RELAPSED AND REFRACTORY MULTIPLE MYELOMA; INTERIM RESULTS OF THE ONGOING, DANISH, INVESTIGATOR-INITIATED, PHASE 2 VICTORIA STUDY
Szabo, A. G., Thorsen, J., Christoffersen, M., Abildgaard, N. & Plesner, T., Jun 2024, In: HemaSphere. 2024/8, Suppl. 1, p. 1608-1610 P910.Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
Open Access
Activities
-
Post-ASH 2019
Plesner, T. (Participant)
17. Dec 2019Activity: Attending an event › Organisation or participation in workshops, courses or seminars
-
American Society of Hematology: 61st Annual Meeting (ASH)
Plesner, T. (Participant)
7. Dec 2019 → 10. Dec 2019Activity: Attending an event › Conference organisation or participation
-
Independent Response Assesment Comittee
Plesner, T. (Participant)
10. Nov 2019 → 12. Nov 2019Activity: Attending an event › Organisation or participation in workshops, courses or seminars
-
DSMG plenummøde
Plesner, T. (Participant)
6. Nov 2019Activity: Attending an event › Organisation or participation in workshops, courses or seminars
-
11th European Myeloma Network
Plesner, T. (Participant)
29. Sept 2019 → 30. Sept 2019Activity: Attending an event › Organisation or participation in workshops, courses or seminars
Press/Media
-
Professor: Medicinrådet fortsætter sin gidselaktion
01/02/2024
1 Media contribution
Press/Media: Press / Media
-
Professor: Medicinrådets afgørelse er et kæmpe tab for patienter med knoglemarvskræft
27/01/2023
1 Media contribution
Press/Media: Press / Media
-
Professor: Medicinrådets afgørelse er chokerende
27/01/2023
1 Media contribution
Press/Media: Press / Media
-
Professor: Medicinrådets afgørelse giver kun mening, hvis man anskuer processen som en gidselaktion
27/01/2023
1 Media contribution
Press/Media: Press / Media
-
Det bliver mere og mere farligt at være en kræftcelle ved knoglemarvskræft
24/10/2022
1 Media contribution
Press/Media: Press / Media
Prizes
-
Ekstern bevilling: Celgene kr. 428.987
Plesner, T. (Recipient), 2013
Prize: Prizes, scholarships, distinctions
-
Ekstern bevilling: BMS kr. 464.022
Plesner, T. (Recipient), 2013
Prize: Prizes, scholarships, distinctions
-
Ekstern bevilling: Roche kr. 254.017
Plesner, T. (Recipient), 2013
Prize: Prizes, scholarships, distinctions
-
Ekstern bevilling: Oncopeptides kr. 50.000
Plesner, T. (Recipient), 2013
Prize: Prizes, scholarships, distinctions
-
Ekstern bevilling: Genmab kr. 834.855
Plesner, T. (Recipient), 2013
Prize: Prizes, scholarships, distinctions